Back to results
US 11,111,295 B2Granted
Antibody for anti-claudin 18A2 and use thereof
AssigneeCafa Therapeutics Limited
InventorsPeng Wang, Hua Jiang, Linlin Yang, Zhimin Shi, Huamao Wang, Zonghai Li
Life of this patent
Estimating the term…
Abstract
Provided in the present invention is an antibody for anti-claudin 18A2 and an immune effector cell targeting claudin 18A2. Also provided are methods for inducing cell death and treating tumours.
Claims29
An antibody or antigen binding unit thereof that specifically binds to claudin 18A2, wherein,
- (a) HCDR1 is SEQ ID NO:31, HCDR2 is SEQ ID NO:32, HCDR3 is SEQ ID NO:33, LCDR1 is SEQ ID NO:34, LCDR2 is SEQ ID NO:35, and LCDR3 is SEQ ID NO:36;
- (b) HCDR1 is SEQ ID NO:37, HCDR2 is SEQ ID NO:38, HCDR3 is SEQ ID NO:39, LCDR1 is SEQ ID NO:
- 40, LCDR2 is SEQ ID NO:
- 41, and LCDR3 is SEQ ID NO:42;
- (c) HCDR1 is SEQ ID NO:43, HCDR2 is SEQ ID NO:44, HCDR3 is SEQ ID NO:45, LCDR1 is SEQ ID NO:46, LCDR2 is SEQ ID NO:47, and LCDR3 is SEQ ID NO:48;
- (d) HCDR1 is SEQ ID NO:49, HCDR2 is SEQ ID NO:50, HCDR3 is SEQ ID NO:51, LCDR1 is SEQ ID NO:52, LCDR2 is SEQ ID NO:53, and LCDR3 is SEQ ID NO:54;
- (e) HCDR1 is SEQ ID NO:31, HCDR2 is SEQ ID NO:83, HCDR3 is SEQ ID NO:33, LCDR1 is SEQ ID NO:34, LCDR2 is SEQ ID NO:35, and LCDR3 is SEQ ID NO:36;
- (f) HCDR1 is SEQ ID NO:31, HCDR2 is SEQ ID NO:84, HCDR3 is SEQ ID NO:33, LCDR1 is SEQ ID NO:34, LCDR2 is SEQ ID NO:35, and LCDR3 is SEQ ID NO:
- 36;
- or
- (g) HCDR1 is SEQ ID NO:49, HCDR2 is SEQ ID NO:85, HCDR3 is SEQ ID NO:51, LCDR1 is SEQ ID NO:52, LCDR2 is SEQ ID NO:53, and LCDR3 is SEQ ID NO:
- 54.
9 more elements
Dependencies are inferred from the claim text.